These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8000764)

  • 1. Gonadotrophin-releasing hormone agonists induce osteoporosis.
    Maillefert JF; Sibilia J; Kuntz JL; Tavernier C
    Br J Rheumatol; 1994 Dec; 33(12):1199-200. PubMed ID: 8000764
    [No Abstract]   [Full Text] [Related]  

  • 2. [Side effects of treatment with the long-acting gonadorelin agonist triptorelin in a case of paraphilia].
    Hoogeveen JH; van der Veer E
    Tijdschr Psychiatr; 2007; 49(2):111-5. PubMed ID: 17290340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
    Waxman J; Man A; Hendry WF; Whitfield HN; Besser GM; Tiptaft RC; Paris AM; Oliver RT
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1387-8. PubMed ID: 2933122
    [No Abstract]   [Full Text] [Related]  

  • 4. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-onset psychosis following androgen deprivation therapy for prostate cancer.
    Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S
    Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
    Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
    Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptorelin in the management of prostate cancer.
    Ploussard G; Mongiat-Artus P
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk?
    Huygh J; Verhaegen A; Goethals K; Cosyns P; De Block C; Van Gaal L
    Crim Behav Ment Health; 2015 Jul; 25(3):226-30. PubMed ID: 25851640
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease flare induced by luteinising hormone releasing hormone analogues in cancer patients.
    Deghenghi R; Misset JL
    Lancet; 1984 Jun; 1(8389):1302. PubMed ID: 6145013
    [No Abstract]   [Full Text] [Related]  

  • 10. Deslorelin. D-Trp-LHRH-PEA, LHRH agonist analogue, Somagard.
    Drugs R D; 1999 Dec; 2(6):420-2. PubMed ID: 10763456
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hormonal pharmacotherapy: balancing between politics and evidence-based medicine].
    van Panhuis PJ
    Tijdschr Psychiatr; 2007; 49(2):117-8. PubMed ID: 17290341
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dramatic aggravation of prostatic cancer at the onset of treatment with an LHRH agonist].
    Boumier P; Koeger AC; Camus JP
    Presse Med; 1985 May; 14(21):1200-1. PubMed ID: 3158996
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
    European and Middle East Orgalutran Study Group
    Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptorelin pamoate (Trelstar).
    Med Lett Drugs Ther; 2002 Jun; 44(1132):51-2. PubMed ID: 12058149
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 16. Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment.
    Kauschansky A; Lurie R; Ingber A
    Acta Derm Venereol; 1997 Jul; 77(4):333. PubMed ID: 9228240
    [No Abstract]   [Full Text] [Related]  

  • 17. Gonadotrophin hormone releasing analogues open new doors in cancer treatment.
    Waxman J
    Br Med J (Clin Res Ed); 1987 Oct; 295(6606):1084-5. PubMed ID: 2961401
    [No Abstract]   [Full Text] [Related]  

  • 18. Local reactions to luteinizing hormone releasing hormone analog therapy.
    Tonini G; Marinoni S; Forleo V; Rustico M
    J Pediatr; 1995 Jan; 126(1):159-60. PubMed ID: 7815213
    [No Abstract]   [Full Text] [Related]  

  • 19. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia.
    Hoogeveen J; Van der Veer E
    J Sex Med; 2008 Mar; 5(3):626-30. PubMed ID: 17971105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.